

September 6, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

We would like to inform that the Company has received request for issue of duplicate share certificate from the following shareholder who has lost his original share certificate.

Folio No.	Name of the Shareholder	Certificate No.	Distinctive Nos.	No. of shares
SAL012775	MATHEWS DANIEL	74575	16822039– 16822043	5

The Company/ Registrar and Transfer Agent (RTA) is in the process of reviewing the request. Duplicate share certificate shall be issued only on receipt of complete documents from the shareholder to the satisfaction of the RTA and the Company including completion of procedural requirements in this regard.

We have also enclosed the email received from RTA for your ready reference.

This is for your information and records.

Thanks and Regards,
For **Strides Pharma Science Limited**,



Manjula Ramamurthy
Company Secretary



Encl: a/a

Kala Raghunath

From: K Ramesh Babu <ramesh.kabothu@kfintech.com>
Sent: 06 September 2021 11:42
To: investors
Cc: Kala Raghunath; Lohith C; A Mohan Kumar
Subject: RE: Request for Duplicate Share Certificate (Folio No. SAL012775)

CAUTION: This email has originated from outside of the organization. Do not click links or open attachments unless you recog

Madam,

We have received email from the shareholder for issue of duplicate share certificate. We request you to kindly intimate the same to Stock Exchanges.

The Holding details are given below. The share certificate is not in postal returns.

S No.	Folio No.	Name(s)	Certificate_No(s)		Distinctive_No(s)		No.of shares
			From	To	From	To	
1	SAL012775	MATHEWS DANIEL	74575	74575	16822039	16822043	5

Regards,
Ramesh

From: investors [mailto:investors@strides.com]
Sent: Monday, September 6, 2021 11:17 AM
To: K Ramesh Babu <ramesh.kabothu@kfintech.com>
Cc: A Mohan Kumar <mohan.a@kfintech.com>; Kala Raghunath <Kala.R@strides.com>
Subject: FW: Request for Duplicate Share Certificate (Folio No. SAL012775)

Dear Ramesh,

Forwarding the email received from Shareholder relating to loss of Share Certificate.

Request you to confirm if the share certificate is lying in your postal returns.

Best Regards,
Investor Relations Team



Strides Pharma Science Limited
Strides House, Bilekahalli, Bannerghatta Road
Bangalore – 560076, India
Board: +91 67840 131/ 732
www.strides.com

From: mathew parel <mathewsdparel@gmail.com>
Sent: 04 September 2021 10:44

To: investors <investors@strides.com>

Subject: Request for Duplicate Share Certificate (Folio No. SAL012775)

CAUTION: This email has originated from outside of the organization. Do not click links or open attachments unless you recog

To,
Strides Pharma Science Ltd.
StridesHouse,Bilekahalli,
Bengaluru.

From
Mathews Daniel (Share Holder)
Parel House,
THEkkemala, Kozhencherry,
Kerala, Pin 689654.

Sir,
I, Mathews Daniel, Share Holder of Strides Pharma Ltd., inform you that, I have lost the Original certificate of above mentioned shares.

So, I hereby request you to provide a new Duplicate Certificate for my future trading,sale, etc.

Appreciate your prompt action.

Thanks & Best Regards

Mathews Daniel
Mob. 8281381948
email- mathewsdparel@gmail.com

Date: 04-09-2021

Disclaimer:

The information contained in this communication is intended solely for the use of the individual or entity to whom it is addressed and others authorized to receive it. This communication or any attachment hereto may contain Unpublished Price Sensitive Information (UPSI) or confidential or legally privileged information. You shall ensure that based on any UPSI of the Company that you may have had access to during the course of your business with the Company, you and your employees shall not make any trade in the shares of the Company. You are required to maintain confidentiality of any UPSI that you may have had access to in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

If you are not the intended recipient, any disclosure, copying, distribution or action taken relying on the contents is prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by responding to this email and then delete it from your system. No liability is accepted for any harm that may be caused to your systems or data by this message.

Unless related to Company business, the opinions, conclusions and other information contained within this email are those of the sender alone and do not necessarily constitute those of Strides Pharma Science Limited. Strides Pharma Science Limited reserves the right to monitor emails sent to or from addresses under its control.